Fibromyalgia: Disease synopsis, medication cost effectiveness and economic burden

PharmacoEconomics

Volumn 32, Issue 5, 2014, Pages 457-466

  Skaer, Tracy L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; GABAPENTIN; MILNACIPRAN; NORTRIPTYLINE; PLACEBO; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; ANXIETY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RETIREMENT; REVIEW; SLEEP DISORDER; UNEMPLOYMENT; COMPLICATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EMPLOYMENT; PERSONALIZED MEDICINE; QUALITY ADJUSTED LIFE YEAR; SEVERITY OF ILLNESS INDEX;

ANALGESICS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; EMPLOYMENT; FIBROMYALGIA; HUMANS; INDIVIDUALIZED MEDICINE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 84902310091     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0137-y     Document Type: Review

References (57)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28.
2. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther. 2010;17(4):418-39.
3. Roskell NS, Beard SM, Zhao Y, et al. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11(6):516-27.
4. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey of five European countries. Semn Arthritis Rheum. 2010;39(6):338-53.
5. Mannerkorpi K, Gard G. Hinders for continue work among persons with fibromyalgia. Musculoskelet Disord. 2012;13:96. doi:10.1186/1471-2474-13-96.
6. Grodman I, Buskila D, Arson Y, et al. Understanding fibromyalgia and its resultant disability. Isr Med Assoc J. 2011;13(12):769-72.
7. Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27(7):547-59.
8. Arnold LM, Hudson JI, Keck PE Jr, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67(8):1219-25. (Pubitemid 44439693)
9. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14(2):127, e1-8.
10. Moore RA, Straube S, Paine J, Phillips CJ, Deny S, McQuay HJ. Fibromyalgia moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain. 2010;149(2):360-4.
11. Knight T, Schaefer C, Chandran A, et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clin Econ Outcomes Res. 2013;5:171-80. doi:10.2147/CEOR.S41111.
12. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. J Clin Pract. 2007;61(9):1498-508. (Pubitemid 47228612)
13. Silverman S, Dukes EM, Johnston SS, et al. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25(4):829-40.
14. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic costs and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30(6):1318-25. (Pubitemid 36666360)
15. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia medical comorbidity, health care costs, and work loss. J Occup Environ Med. 2008;50(1):13-24.
16. Wolfe F, Clauw DJ, Fitzcharles M, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600-10.
17. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome. J Clin Rheumatol. 2013;19(2):72-7.
18. Arnold JM, Clauw DJ, Dunegan LJ, Turk DC. A framework for fibromyalgia management for primary care providers. May Clin Proc. 2012;87(5):488-96.
19. Smith HS, Bracken D, Smith JM. Pharmacotherapy for fibromyalgia. Front Pharmacol. 2011;2:17 (Epub 2011 Mar 31).
20. Firestone KA, Holton KF, Mist SD, Wright CL, Jones KD. Optimizing fibromyalgia management. Nurs Pract. 2012;37(4):12-21.
21. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297-302.
22. Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs. 2010;70(1):1-14.
23. Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ. 2012;15(3):481-92.
24. Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin. 2010;26(4):965-75.
25. Beard SM, Roskell N, Le TK, et al. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ. 2011;14(4):463-76.
26. Ornelas HA, Buzzo AR, Garcia L, et al. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico. Reumatol Clin. 2012;8(3):120-7.
27. Cappelleri JC, Bushmakin AG, Zlateva G, Chandran A. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin. J Med Econ. 2013;16(1):55-61.
28. Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil. 2005;27(12):685-94.
29. Henriksson CM, Liedberg GM. Factors of importance for work disability in women with fibromyalgia. J Rhematol. 2000;27(5):1271-6.
30. Assefi NP, Coy TV, Uslan D, et al. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions. J Rheumatol. 2003;39(4):804-8. (Pubitemid 36402776)
31. Gerdle B, Bjork J, Coster L, et al. Prevalence of widespread pain and associations with work status: a population study. BMC Musculoskelet Disord. 2008;9:102.
32. Kurtze N, Gundersen KT, Sveback S. The impact of perceived physical dysfunction, health habits and affective symptoms on employment status among fibromyalgia support group members. J Musculoskelet Pain. 2001;9(2):39-53. (Pubitemid 32995758)
33. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13(4):199-201. (Pubitemid 47356787)
34. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8(1):27.
35. Evans CJ, Parthan A, Le K. Economic and humanistic burden of fibromyalgia in the USA. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):303-14. (Pubitemid 43984122)
36. Kivimaki M, Leino-Arjas P, Kaila-Kangas L, et al. Increased absence due to sickness among employees with fibromyalgia. Ann Rheum Dis. 2007;66(1):65-9. (Pubitemid 46044862)
37. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate, and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.
38. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.
39. Angst F, Verra ML, Lehmann S, et al. Responsiveness of five condition-specific and generic outcomes assessment instruments for chronic pain. BMC Med Res Methodol. 2008;8:26.
40. Birtane M, Uzuncan K, Tastekin N, et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol. 2007;26(5):679-84. (Pubitemid 46554072)
41. Perrot S, Winkelmann A, Dukes E, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract. 2010;64(8):1100-8.
42. Yilmaz F, Sahin F, Ergoz E, et al. Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol. 2008;27(3):327-32.
43. Pagano T, Matsutani LA, Ferreira EA, et al. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J. 2004;122(6):252-8. (Pubitemid 40185907)
44. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115-26. (Pubitemid 350294025)
45. Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31(7):1391-8. (Pubitemid 38879207)
46. Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumotol. 2004;31(8):1621-9. (Pubitemid 39006646)
47. Hughes G, Martines C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum. 2006;54(1):177-83. (Pubitemid 43122200)
48. Annemans L, Wesseley S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895-902. (Pubitemid 351364892)
49. Chandran A, Schaefer C, Ryan K, et al. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age US adults. JMCP. 2012;18(6):415-26.
50. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40(9):1560-70. (Pubitemid 27426148)
51. Haviland MG, Banta JE, Przekop P. Hospitalisation charges for fibromyalgia in the United States, 1999-2007. Clin Exp Rheumatol. 2012;30(supple 74):129-35.
52. Kim SK, Kim SH, Lee CK, et al. Effect of fibromyalgia syndrome on the health-related quality of life and economic burden in Korea. Rheumatology. 2013;52(2):311-20.
53. Winkelmann A, Perrot S, Schaefer C, et al. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy. 2011;9(2):125-36.
54. Perrot S, Schaefer C, Knight T, et al. Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains. BMC Musculoskelet Disord. 2012;13:22. doi:10.1186/1471-2474-13-22.
55. Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosin spondylitis. Ann Rheum Dis. 2005;64(3):396-402. (Pubitemid 40283049)
56. Rivera J, Rejas-Gutierrez J, Vallego MA, et al. Prospective study of the use of healthcare resources and economic costs in patients with fibromyalgia after treatment in routine medical practice. Clin Exp Rheumatol. 2012;30(Suppl 74):S31-8.
57. Zijlstra TR, Braakman-Jansen LM, Taal E, et al. Cost-effectiveness of spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford). 2007;46(9):1454-9. (Pubitemid 47317094)